Brief: Appili Therapeutics Acquires Clinical Stage Antifungal Program From Fujifilm Toyama Chemical
21/11/2019 09:05
Nov 21 (Reuters) - Appili Therapeutics Inc APLI.V :
* APPILI THERAPEUTICS ACQUIRES CLINICAL STAGE ANTIFUNGAL
PROGRAM
FROM FUJIFILM TOYAMA CHEMICAL
* APPILI THERAPEUTICS - FUJIFILM TOYAMA CHEMICAL ELIGIBLE
FOR
FUTURE REGULATORY, COMMERCIAL MILESTONES PAYMENTS AND ROYALTY ON
FUTURE NET SALES
Source text for Eikon: ID:nBw33Fr0Qa
Further company coverage: APLI.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez